Skip to content
Menu

WM Technology, Inc. MAPS

Full chart Compare
Set alert

Price alert · MAPS

All alert types
0.16 USD 0.00 (+2.55%)

As ofNov 20, 2026, 3:58 PM EST

0.1505 Day range 0.1694
0.157 52-week range 1.16
YTD
-80.48%
1 year
-78.53%

Discussion (1)

VICKY HANUKA MAPS 3 years ago #1

"During this quarter, we executed an agreement with United States Air Force Academy ("USAFA") for an initial amount of US$7.3million in funding from the Defense Threat Reduction Agency and USAFA for our ATI-1701 vaccine, a crucial defense against Tularemia, which is a top-priority biothreat. Our partnership with USAFA and the recent agreement execution will enable us to advance this program towards an Investigational New Drug ("IND")," said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. "Additionally, securing US patent coverage through at least 2039 for ATI-1501, our Metronidazole formulation, is a significant milestone leading up to the anticipated FDA Prescription Drug User Fee ("PDUFA") date on September 23, 2023. We look forward to receiving milestone payments and royalties from our partner, Saptalis Pharmaceuticals LLC ("Saptalis"), in the coming quarters based on their submission and commercialization plans. These achievements are expected to position us with the required resources to continue to make progress in advancing our infectious disease assets."

Sign in to join the discussion